Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM).

Publication ,  Conference
Gasparetto, C; Lentzsch, S; Schiller, GJ; Callander, NS; Tuchman, S; Bahlis, NJ; White, D; Chen, C; Baljevic, M; Sutherland, HJ; Kotb, R ...
Published in: JOURNAL OF CLINICAL ONCOLOGY
2020

Duke Scholars

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

2020

Volume

38

Issue

15

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gasparetto, C., Lentzsch, S., Schiller, G. J., Callander, N. S., Tuchman, S., Bahlis, N. J., … Lipe, B. (2020). Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).
Gasparetto, Cristina, Suzanne Lentzsch, Gary J. Schiller, Natalie Scott Callander, Sascha Tuchman, Nizar J. Bahlis, Darrell White, et al. “Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.
Gasparetto C, Lentzsch S, Schiller GJ, Callander NS, Tuchman S, Bahlis NJ, et al. Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM). In: JOURNAL OF CLINICAL ONCOLOGY. 2020.
Gasparetto, Cristina, et al. “Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM).JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 15, 2020.
Gasparetto C, Lentzsch S, Schiller GJ, Callander NS, Tuchman S, Bahlis NJ, White D, Chen C, Baljevic M, Sutherland HJ, Kotb R, Sebag M, LeBlanc R, Venner CP, Bensinger W, Rossi AC, Sheehan H, Arazy M, Kai K, Lipe B. Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM). JOURNAL OF CLINICAL ONCOLOGY. 2020.

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

2020

Volume

38

Issue

15

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences